在接受salmeterol的持久性喘患者中,吸入性皮质类固醇的减少和消除:一项随机对照试验
R F Lemanske1, C A Sorkness, E A Mauger
1University of Wisconsin Children's Hospital, 600 Highland Ave, K4/916-9988, Madison, WI 53792, USA. rfl@medicine.wisc.edu
JAMA
|May 23, 2001
概括
在吸入性皮质类固醇 (ICS) 治疗中添加沙米特醇可以使持续性喘的ICS剂量减少50%. 然而,完全取消ICS治疗会导致严重的喘控制损失,因此不建议.
科学领域:
- 肺部病理学 肺部病理学
- 临床药理学 临床药理学
背景情况:
- 吸入的长效β2-激动剂 (LABA) 是有效的补充疗法,用于改善喘控制,当与吸入性皮质类固醇 (ICS) 结合使用时.
- 持久性喘通常需要持续使用ICS进行治疗,但与LABA使用一起减少或消除ICS治疗的潜力仍然是研究领域.
研究的目的:
- 评估减少或取消吸入性皮质类固醇 (ICS) 治疗的可行性,在持久性喘患者接受长效β2-激动剂 (LABA) 补充治疗.
主要方法:
- 这是一项为期24周的随机,双模拟,并行组试验,涉及175名患有持续性喘的患者,这些患者在吸入的三氨乙化物上得到了亚最佳控制.
- 患者接受了额外的salmeterol xinafoate,随后随机选择要么将ICS减少50%,然后消除它,要么继续标准的ICS治疗 (主动控制).
- 主要结局指标是喘治疗失败的时间.
主要成果:
- 在接受沙米特醇的患者中,降低了50%的ICS,在8周后,与活跃对照组 (2.8%) 相比,治疗失败的趋势增加了 (8.3%).
- 在萨尔米特醇组中,完全取消ICS治疗导致治疗失败率 (46.3%) 在8周后明显高于活跃对照组 (13.7%).
- 在ICS消除后,治疗失败的相对风险在降低剂量组与活性对照组相比是4.3倍高 (P<.001).
结论:
- 对于持久性喘患者,其症状随着沙米特醇的添加而改善,在不显著失去喘控制的情况下,可以减少50%的吸入性皮质类固醇 (ICS) 剂量.
- 在这种患者群体中,完全取消ICS治疗会导致喘控制的显著恶化,因此不建议.
- 这些发现支持在添加LABA用于喘管理时ICS剂量减少而不是消除的策略.
相关概念视频
Drugs Used in Lower Respiratory Disorders: Overview
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Antiasthma Drugs: β2-Adrenoceptor Agonists
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Inhaled Medications
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
Chronic Obstructive Pulmonary Disease II: Emphysema
Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.


